Your session is about to expire
← Back to Search
Ipatasertib + Endocrine Therapy for Breast Cancer
Study Summary
This trial is testing a new combination therapy for breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 242 Patients • NCT04177108Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain metastases are stable, and I haven't taken steroids for over a month.I have previously been treated with mTOR or PI3K inhibitors.I am a premenopausal woman on hormone therapy with low estrogen levels.I have at least one cancer lesion that can be measured.I practice total abstinence as my usual form of lifestyle.I am using or will use effective birth control during and 8 weeks after the study.I am a woman who has been sterilized through surgery at least six weeks ago.I do not have uncontrolled heart disease or abnormal heart rhythms.I haven't taken strong CYP3A affecting drugs in the last 14 days or longer.My kidneys are working well enough (creatinine clearance ≥ 30 mL/min).I have had both of my ovaries surgically removed.I have diabetes requiring insulin or stable oral medication for at least 2 weeks.I have previously taken aromatase inhibitors.I stopped taking CDK 4/6 inhibitor due to severe side effects.I am a postmenopausal woman with advanced or metastatic breast cancer.I am not pregnant.Your blood sugar levels when you haven't eaten should be below 140 mg/dL, and your average blood sugar over the past few months should be less than 7.My cancer has worsened after treatment, including hormone therapy.I am HIV-positive and not on combination antiretroviral therapy.My liver functions are within the required range.I am a woman 60 years old or younger.I have previously been treated with fulvestrant.I use a highly effective form of birth control.I have previously used an AKT inhibitor.I am a woman older than 60 years.Your heart's pumping ability is normal, and it's above 50%.I am able to care for myself and perform daily activities.I stopped my breast cancer treatments 14-28 days ago, depending on the type.My blood tests show normal white blood cells, hemoglobin, and platelets.I haven't had chemotherapy or radiotherapy in the last 4 weeks, or I've recovered from its side effects.I am a woman over 18 with HR+/HER2- breast cancer, confirmed by biopsy.My LH and FSH levels indicate I am postmenopausal.I do not have any serious illnesses or mental health issues that would stop me from following the study rules.
- Group 1: Fulvestrant + Ipatasertib
- Group 2: Aromatase Inhibitor + Ipatasertib
- Group 3: Fulvestrant + Ipatasertib +Palbociclib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are recruitment activities in progress for this experiment?
"Affirmative. Clinicaltrials.gov currently displays that this clinical trial, which was first submitted on May 30th 2019 and recently revised October 25th 2021, is actively seeking participants. This study requires 60 people to be enrolled at one site."
What indications are typically addressed with Ipatasertib?
"Ipatasertib is an effective therapeutic option for cases in which disease progression has been identified. It can also be employed to treat postmenopausal women and those receiving tamoxifen treatment as well as advanced directives."
How many participants is this research endeavor encompassing?
"Indeed, the records on clinicaltrials.gov report that this research project is actively recruiting participants. The trial was made available to public view on May 30th 2019 and has been updated as recently October 25th 2021. So far, 60 patients are needed from a single medical site for inclusion in the study."
Has the FDA sanctioned Ipatasertib for use?
"The safety profile of Ipatasertib was rated a 1 due to the limited clinical evidence available. As this is a phase 1 trial, there is only preliminary data supporting both its efficacy and safety."
What other investigations have been executed regarding Ipatasertib?
"At present, 357 clinical trials for Ipatasertib are underway with 71 in the final phase of testing. Shanghai is a major hub for these tests with 19871 locations running experiments on this medication."
Share this study with friends
Copy Link
Messenger